Emerging lipid lowering agents targeting LDL cholesterol.

Emerging lipid lowering agents targeting LDL cholesterol. Postgrad Med. 2020 Apr 03;: Authors: Wójcik C Abstract Atherosclerotic cardiovascular disease (ASCVD) is the main cause of morbidity and mortality in the US. ASCVD is caused by elevated levels of ApoB lipoproteins, which over many years penetrate the arterial subendothelial space leading to plaque growth and eventually rupture causing clinical symptoms. ApoB lipoprotein levels are approximated in clinical practice by LDL-C measurement. LDL-C lowering agents (statins, ezetimibe and PCSK9 inhibitors) reduce cardiovascular risk in primary and secondary prevention proportionally to LDL-C reduction (23% per 1 mmol/L of LDL). However, for a variety of reasons, many patients do not achieve their recommended LDL-C levels using currently available therapies. This has prompted the development of new LDL-C lowering drugs in the hope to reduce cardiovascular risk, such as bempedoic acid, inclisiran, gemcabene and evinacumab. Drugs targeting other lipids (triglycerides, HDL-C, lipoprotein (a)), intravascular inflammation or acting by other mechanisms also have a role in atherosclerosis prevention, however, they will not be covered in this review. PMID: 32243228 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research

Related Links:

(CNN) — Still taking a daily aspirin to ward off heart attacks? You might want to think again, according to a new review. Aspirin is still one of the most commonly used medications in the world, even though it’s no longer recommended as a preventative by many health authorities. There is no evidence that low-dose aspirin — less than 325 milligrams a day — should be taken by most adults in good cardiovascular health, according to a new review of existing research that published Wednesday in the British Journal of Clinical Pharmacology. The review, which focused on the risks and benefits of low-dose d...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News aspirin CNN Source Type: news
Statin-associated necrotizing myopathy (SANM) is a rare autoimmune disorder caused by administration of statins. SANM is characterized by weakness due to necrosis and regeneration of myofibers. Here we report ...
Source: BMC Pulmonary Medicine - Category: Respiratory Medicine Authors: Tags: Case report Source Type: research
AbstractObjectivesTo assess the prevalence of statin usage, intensity of statin therapy, and serum LDL cholesterol levels achieved in clinical diabetes mellitus population to analyze whether the recommendations of American College of Cardiology/American Heart Association ’s cholesterol guidelines 2013 (ACC/AHA cholesterol guidelines 2013) are achieved in them.MethodsFasting lipid profile values, prevalence of statin usage, and intensity of statin therapy among 306 diabetes mellitus patients in the age group of 40 to 75  years, visiting the medicine department of a secondary care hospital, were noted. Results wer...
Source: International Journal of Diabetes in Developing Countries - Category: Endocrinology Source Type: research
Conclusions Although clinical data supporting an influence of all these drugs on the course of the disease are limited, this is an interesting background for further research that might help unravel the complex mechanisms underlying the link between COVID-19 and diabetes.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research
AbstractPurpose of ReviewThis review focuses on recent evidence examining the role triglycerides (TG) and triglyceride-enriched lipoproteins (TGRL) play in atherosclerotic cardiovascular disease (ASCVD). It also provides a succinct overview of current and future TG-lowering therapies for ASCVD risk reduction.Recent FindingsEpidemiological and Mendelian randomization studies have consistently shown that TGRL are strongly associated with ASCVD. REDUCE-IT demonstrated cardiovascular benefit with icosapent ethyl in high-risk patients with hypertriglyceridemia on statin therapy. Polymorphisms inAPOC3 andANGPTL3 are associated w...
Source: Current Atherosclerosis Reports - Category: Cardiology Source Type: research
AbstractPurpose of ReviewStatins represent the cornerstone for the treatment of hypercholesterolemia, although muscle-related side effects and dysregulation of glucose metabolism have strongly limited their adherence and compliance especially in primary prevention therapy. The purpose of the present review is to provide the most recent evidence of the efficacy and safety of statins in monotherapy or combination with new lipid-lowering drugs.Recent FindingsRecent “life-long” analysis conducted on young familial hypercholesterolemia patients, elderly hypocholesterolemic subjects, and from a 20-year follow-up of r...
Source: Current Atherosclerosis Reports - Category: Cardiology Source Type: research
AbstractPurpose of ReviewIn our pilot study, we aimed to determine how many patients with the statin intolerance history referred to the specialized center for the diagnostics and treatment of lipoprotein metabolism disorders really suffer from a complete statin intolerance. The purpose of the study was to prove that complete statin intolerance is overestimated and overdiagnosed, and with the detailed knowledge of the issue and patient approach, it is possible to find an appropriate statin treatment for the most of patients.Recent FindingsWith the increasing number of statin users worldwide, the issue of statin intolerance...
Source: Current Atherosclerosis Reports - Category: Cardiology Source Type: research
ConclusionsChanges to pre-specified aspects of the design and analysis of an ongoing RCT may be a necessary response to unforeseen circumstances. Such changes risk introducing a bias if undertaken with knowledge of treatment allocation. Legitimate changes need to be adequately documented to provide assurance to all stakeholders of their validity.
Source: Trials - Category: Research Source Type: clinical trials
Germinal center (GC) responses require B cells to respond to a dynamic set of intercellular and microenvironmental signals that instruct B cell positioning, differentiation, and metabolic reprogramming. RHO-associated coiled-coil–containing protein kinase 2 (ROCK2), a serine-threonine kinase that can be therapeutically targeted by ROCK inhibitors or statins, is a key downstream effector of RHOA GTPases. Although RHOA-mediated pathways are emerging as critical regulators of GC responses, the role of ROCK2 in B cells is unknown. Here, we found that ROCK2 was activated in response to key T cell signals like CD40 and IL-...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
We report a case of ANCA-associated vasculitis coexisting with cholesterol emboli. A 76-year-old woman was diagnosed with ANCA-associated interstitial pneumonitis. She rapidly developed progressive glomerulonephritis, purpura, and peripheral sensory nerve disorder. A kidney biopsy revealed that renal dysfunction was caused by vasculitis of the interlobular arteries and cholesterol emboli. A skin biopsy revealed that purpura was caused by cholesterol emboli. Glucocorticoid and statin therapies were administered. Thereafter, the renal function and other symptoms improved and stabilized. The representative symptoms of ANCA-as...
Source: The Tohoku Journal of Experimental Medicine - Category: Research Authors: Tags: Tohoku J Exp Med Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Heart | Internal Medicine | Statin Therapy | Vytorin | Zetia